Deerfield Entities and James E. Flynn Report 5.80% Ownership in BioCryst Pharmaceuticals

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have jointly filed a Schedule 13G with the SEC, reporting a 5.80% ownership in BioCryst Pharmaceuticals, Inc. The filing indicates that these entities and individuals collectively own 12,169,000 shares of the company's common stock. The shares are held by Deerfield Partners, L.P., with Deerfield Mgmt, L.P. serving as the general partner and Deerfield Management Company, L.P. acting as the investment advisor. James E. Flynn, a United States citizen, is also part of this group. The filing certifies that the securities were not acquired for the purpose of influencing the control of the issuer.